Status and phase
Conditions
Treatments
About
This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
94 participants in 7 patient groups
Loading...
Central trial contact
Qian Jia
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal